Article

Endophthalmitis: prevention better than cure

According to Zdenek Gregor of Moorfields Eye Hospital, London, UK, prevention of endophthalmitis will always be preferable to a cure. While the use of preoperative povidone iodine has managed to decrease the incidence of the infection, the hope is that per-operative intracameral antibiotics will further fuel a decrease in incidence of this worrying consequence of cataract surgery.

According to Zdenek Gregor of Moorfields Eye Hospital, London, UK, prevention of endophthalmitis will always be preferable to a cure. While the use of preoperative povidone iodine has managed to decrease the incidence of the infection, the hope is that per-operative intracameral antibiotics will further fuel a decrease in incidence of this worrying consequence of cataract surgery.

Speaking at the "Endophthalmitis following cataract surgery" symposium, Dr Gregor reminded his audience that the visual prognosis for postoperative endophthalmitis has improved dramatically since the 1960s. At that time, around 75% of cases resulted in a loss of hand motion visual acuity (HM), however, the prospects are now much brighter with vision of 6/12 or more being seen in between 53 to 90% of patients. This improvement came about when it was realised that damage to the posterior segment could be minimised with immediate administration of intravitreal antibiotics, with or without pars plana vitrectomy.

The pivotal Endophthalmitis Vitrectomy Study (EVS) of 1995 confirmed the value of this procedure, finding that the systemic use of the antiobiotics on the day was not useful whereas immediate vitrectomy yielded positive results, but only in those patients with the poorest visual function (<HM).

Dr Gregor then moved on to outline the most recent developments. Vitrectomy techniques have advanced considerably since the EVS report, and are much safer even in the absence of posterior vitreous detachment. Wide-angle viewing has allowed for larger laboratory samples, earlier and more extensive evacuation of causative organisms and toxins, greater access to the aqueous and for better distribution of injected antibiotics. In addition to these technical advancements developments in drug use has also had an impact. Intraocular steroids are gaining credibility as a method of reducing the effects of the inflammatory cytokines on the retina and new systemic antibiotics, such as fourth generation fluoroquinolones, are proving effective against Gram positive and negative organisms.

Dr Gregor's presentation supported the notion that prevention is indeed better than a cure, and with the evolution of a new generation of antibiotics and steroids, such as the per-operative intracameral antibiotics currently being tested in the ESCRS-sponsored study, the future of endophthalmitis treatment is looking promising.

Ophthalmology Times Europe reporting from the XXIV Congress of the ESCRS, London, 9-13 September, 2006.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.